Sanofi-aventis announced today that the European Commission has approved 2 new indications for Taxotere® (docetaxel) Injection Concentrate for treatment of breast cancer.
The first granted Taxotere®, in combination with doxorubicin and cyclophosphamide, for the adjuvant treatment of patients with operable node-positive breast cancer.
A second granted Taxotere®, in combination with Herceptin® (trastuzumab), for the treatment of patients with metastatic breast cancer whose tumors over-express the Her2 gene.
The first granted Taxotere®, in combination with doxorubicin and cyclophosphamide, for the adjuvant treatment of patients with operable node-positive breast cancer.
A second granted Taxotere®, in combination with Herceptin® (trastuzumab), for the treatment of patients with metastatic breast cancer whose tumors over-express the Her2 gene.
